Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3744 |
Name | cervical squamous cell carcinoma |
Definition | A cervix carcinoma that has_material_basis_in squamous cells of the cervix. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer cervical cancer cervix carcinoma cervical squamous cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA E542K | Gemcitabine + LY2780301 | cervical squamous cell carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01101451 | Phase III | Cisplatin | Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery | Unknown status | USA | 2 |
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Completed | USA | NLD | ITA | FRA | ESP | DEU | CAN | 0 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | FRA | ESP | CAN | 1 |
NCT02257528 | Phase II | Nivolumab | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | Active, not recruiting | USA | 0 |
NCT02348398 | Phase II | Pazopanib + Topotecan | Phase II Study of Pazopanib and Topotecan in Cervical Cancer | Withdrawn | 0 | |
NCT02466971 | Phase III | Cisplatin Cisplatin + Triapine | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers | Active, not recruiting | USA | CAN | 1 |
NCT02558348 | Phase Ib/II | Anlotinib | Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) | Terminated | USA | 0 |
NCT02584478 | Phase Ib/II | Anlotinib + Carboplatin + Paclitaxel | Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | Active, not recruiting | USA | ITA | GBR | ESP | 2 |
NCT02595879 | Phase I | Cisplatin + Triapine | Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer | Active, not recruiting | USA | 0 |
NCT02646319 | Phase I | Nab-rapamycin | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | Completed | USA | 0 |
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
NCT02853604 | Phase III | ADXS11-001 | Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV) | Terminated | USA | POL | ESP | CAN | BRA | ARG | 8 |
NCT02856425 | Phase I | Nintedanib + Pembrolizumab | Trial Of Pembrolizumab And Nintedanib (PEMBIB) | Recruiting | FRA | 0 |
NCT03108495 | Phase II | LN-145 | Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CHE | 0 |
NCT03212469 | Phase Ib/II | Durvalumab + Tremelimumab | A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer (ABIMMUNE) | Active, not recruiting | FRA | 0 |
NCT03357757 | Phase II | Avelumab + Valproic acid | Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) | Active, not recruiting | CAN | 0 |
NCT03367871 | Phase II | Cisplatin + Paclitaxel + Pembrolizumab | Combination Pembrolizumab, Paclitaxel and Cisplatin in Patients With Cervical Cancer | Terminated | USA | 0 |
NCT03438396 | Phase II | Tisotumab vedotin-tftv | A Trial of Tisotumab Vedotin in Cervical Cancer | Completed | USA | SWE | ITA | ESP | DNK | DEU | CZE | BEL | 0 |
NCT03495882 | Phase Ib/II | Balstilimab + Zalifrelimab | Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) | Completed | USA | POL | HUN | ESP | BRA | AUS | 3 |
NCT03556839 | Phase III | Atezolizumab + Bevacizumab + Cisplatin + Paclitaxel Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (BEATcc) | Active, not recruiting | USA | SWE | NOR | ITA | FRA | ESP | DEU | 1 |
NCT03612791 | Phase II | Cisplatin Atezolizumab + Cisplatin | Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (ATEZOLACC) | Active, not recruiting | FRA | 0 |
NCT03635567 | Phase III | Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab | Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) | Completed | USA | TUR | ITA | ISR | FRA | ESP | DEU | CAN | AUS | ARG | 9 |
NCT03644342 | Phase Ib/II | Niraparib | Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix (NIVIX) | Terminated | USA | 0 |
NCT03738228 | Phase I | Atezolizumab + Cisplatin | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer | Active, not recruiting | USA | 0 |
NCT03786081 | Phase Ib/II | Bevacizumab + Tisotumab vedotin-tftv Carboplatin + Tisotumab vedotin-tftv Pembrolizumab + Tisotumab vedotin-tftv | Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer | Active, not recruiting | USA | TUR | NLD | ITA | IRL | GBR | ESP | DNK | CZE | BEL | 0 |
NCT03830866 | Phase III | Durvalumab Cisplatin + Durvalumab Carboplatin + Durvalumab | Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA) | Completed | USA | POL | HUN | BRA | 11 |
NCT03833479 | Phase II | Dostarlimab-gxly | TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation (ATOMICC) (ATOMICC) | Active, not recruiting | TUR | ESP | 0 |
NCT03894215 | Phase II | Balstilimab Balstilimab + Zalifrelimab | Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer | Active, not recruiting | USA | BRA | 5 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | ESP | CAN | BEL | 0 |
NCT03912415 | Phase III | Bevacizumab + Cisplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel + Prolgolimab | Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA) (FERMATA) | Recruiting | TUR | 3 |
NCT03946358 | Phase II | Atezolizumab + UCPVax | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) (VolATIL) | Active, not recruiting | FRA | 0 |
NCT04065269 | Phase II | Ceralasertib + Olaparib Ceralasertib | ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI) | Recruiting | GBR | CAN | 0 |
NCT04205799 | Phase II | Cabozantinib | Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure (CABOCOL-01) | Completed | FRA | 0 |
NCT04221945 | Phase III | Cisplatin + Pembrolizumab Cisplatin | Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11) | Active, not recruiting | USA | TUR | SWE | NOR | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | 11 |
NCT04230954 | Phase II | Cabozantinib + Pembrolizumab | Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer | Terminated | USA | 0 |
NCT04238988 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer (MITO CERV 3) | Unknown status | ITA | 0 |
NCT04246489 | Phase II | Bintrafusp alfa | Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer | Completed | USA | HUN | FRA | ESP | BRA | BEL | AUS | ARG | 4 |
NCT04256213 | Phase 0 | Ipilimumab + Nivolumab | COL Immunotherapy Before Radiochimio + Ipilimumab (COLIBRI) | Active, not recruiting | FRA | 0 |
NCT04300647 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer (SKYSCRAPER-04) | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | CAN | BRA | AUS | 8 |
NCT04357873 | Phase II | Pembrolizumab + Vorinostat | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations (PEVOsq) | Active, not recruiting | FRA | 0 |
NCT04380805 | Phase II | Cadonilimab | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer | Completed | USA | NZL | AUS | 0 |
NCT04381650 | Phase Ib/II | Pembrolizumab + Subasumstat | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | POL | LVA | LTU | HRV | CHE | BRA | 2 |
NCT04405349 | Phase II | Atezolizumab + VB10.16 | Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer | Completed | POL | NOR | DEU | CZE | BGR | BEL | 0 |
NCT04487587 | Phase II | Cediranib + Olaparib | A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer (COMICE) | Unknown status | GBR | 0 |
NCT04551950 | Phase I | Bevacizumab + Bintrafusp alfa + Carboplatin + Paclitaxel Bevacizumab + Bintrafusp alfa + Cisplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Paclitaxel Bintrafusp alfa + Cisplatin Bintrafusp alfa + Carboplatin + Paclitaxel | Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTRAPID 046) | Completed | USA | ESP | 1 |
NCT04580771 | Phase II | Cisplatin + PDS0101 | A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial | Active, not recruiting | USA | 0 |
NCT04630353 | Phase I | HB-201 | A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer | Terminated | USA | 0 |
NCT04646005 | Phase II | Cemiplimab + ISA101b | Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy | Completed | USA | NLD | ITA | ESP | BRA | BEL | 2 |
NCT04652076 | Phase Ib/II | Carboplatin + NP137 + Paclitaxel Trevatide + Pembrolizumab NP137 + Pembrolizumab Carboplatin + NP137 + Paclitaxel Carboplatin + Paclitaxel | GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab (GYNET) | Active, not recruiting | FRA | 0 |
NCT04697628 | Phase III | Topotecan Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301) | Active, not recruiting | USA | SWE | POL | NOR | NLD | ITA | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | ARG | 7 |
NCT04943627 | Phase III | Topotecan Balstilimab Gemcitabine Irinotecan Pemetrexed Disodium Vinorelbine | Balstilimab in Patients With Recurrent Cervical Cancer. | Withdrawn | USA | 1 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | Recruiting | USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | 4 |
NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | FRA | ESP | DEU | CAN | 5 |
NCT05337735 | Phase II | XmAb20717 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | Suspended | USA | 0 |
NCT05475171 | Phase II | MGD019 | Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) | Recruiting | USA | 0 |
NCT05492123 | Phase II | Ipilimumab + Nivolumab Cisplatin Cisplatin + Nivolumab Carboplatin + Nivolumab Carboplatin | Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer | Recruiting | BRA | 0 |
NCT05521997 | Phase II | Cisplatin + Telaglenastat Cisplatin | Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | Not yet recruiting | USA | 0 |
NCT05784688 | Phase Ib/II | Pembrolizumab + TU2218 | Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 0 |
NCT06079671 | Phase III | MEDI5752 | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (eVOLVECervical) | Recruiting | USA | TUR | POL | NOR | ITA | ESP | DNK | CAN | BRA | 8 |
NCT06099418 | Phase II | VB10.16 Atezolizumab + VB10.16 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. | Withdrawn | 0 | |
NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT06238479 | Phase I | LY4101174 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | Recruiting | USA | ESP | BEL | AUS | 1 |
NCT06266338 | Phase II | Lenvatinib + Pembrolizumab | Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix) | Recruiting | USA | 0 |
NCT06444815 | Phase I | VET3-TGI Pembrolizumab + VET3-TGI | A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001) | Recruiting | USA | 0 |
NCT06457997 | Phase I | PHN-010 | A Study of PHN-010 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06459180 | Phase III | Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine Topotecan SKB264 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | Recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | FIN | ESP | DNK | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 7 |
NCT06465069 | Phase I | LY4052031 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01) | Recruiting | USA | GBR | ESP | 1 |
NCT06543576 | Phase Ib/II | Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab | External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer | Not yet recruiting | USA | 0 |
NCT06598371 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + KSQ-004EX KSQ-004EX | A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT06639191 | Phase I | 177Lu-AKIR001 | [177Lu]Lu-AKIR001 First-in-human Study (AKIR001) | Not yet recruiting | SWE | 0 |
NCT06660654 | Phase II | Raludotatug deruxtecan | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | Not yet recruiting | USA | 0 |